New guide to shorter regimen for treating drug-resistant TB

DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. The Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and Treatment Action Group (TAG) released a new brief explaining what the shorter regimen is, who can receive it, and its advantages and disadvantages.

If you want to learn even more, check out the webinar TAG, ACTION and DR-TB STAT held on the phase III trial of the shorter regimen and on the phase III trial of newer TB drug, delamanid, here.

Source: Treatment Action Group

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Treatment Action Group, DR-TB STAT

Published: March 15, 2018, 9:44 p.m.

Last updated: March 16, 2018, 6:03 a.m.

Print Share